Bradley Monk, MD, FACOG, FACS, discusses the relevance of FRα, HER2, and PD-L1 expression in influencing decision-making in recurrent ovarian cancer.
Bradley Monk, MD, FACOG, FACS
Advertisement
Bradley Monk, MD, FACOG, FACS is a board-certified gynecologic oncologist with Florida Cancer Specialists & Research Institute and medical director of the Late-Stage Clinical Research Program.
Articles by Bradley Monk, MD, FACOG, FACS
Bradley Monk, MD, FACOG, FACS, discusses the FDA’s accelerated approval of avutometinib and defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
5